Aesica
+ - Contact Details
Address
Aesica Pharmaceuticals Ltd
Shotton Lane
Windmill Industrial Estate
Cramlington
Northumberland
NE23 3JL
+ - Chemistry
+ - APIs
+ - NSAIDs
+ - Flurbiprofen
+ - Aesica Pharmaceuticals has been granted a Certificate of Suitability
for Flurbiprofen by the European Directorate for the Quality of
Medicines (EDQM). The certificate, number R0-CEP 2003-270-Rev 00,
was awarded on the 24th March 2006 and confirms that Aesica's
Flurbiprofen is compliant with the requirements of the European
Pharmacopoeial monograph.
+ - The Merck Index 12th ed
4234 Flurbiprofen US pat 3,755,427
to Boots
+ -
There must be a better synthesis!
+ - Sodium Flurbiprofen
Require synthesis details
+ - R-Flurbiprofen
+ -
~>Myriad Pharmaceuticals Inc and FlurizanŽ
Require synthesis details
+ - S-Flurbiprofen
Require synthesis details
+ - Paroxetine
+ -
Paroxetine is an antidepressant of the
selective serotonin reuptake inhibitor
(SSRI) type. It is effective in treating
depression as well as a spectrum of
anxiety disorders ranging from panic
attacks to phobias.
+ - Merk Index 12th ed
US pats 3,912,743; 4,007,196 (1974, 1975,
1977 all to Ferrosan); 4,721,723 (Beecham)
+ - US 3,912,743
+ - US 3,912,743
US 2,506,458 - Arecoline
US 2,569,182 - Arecoline
+ - US 4,007,196
+ - US 4,007,196 Menthol ester resolution to give SM
Converted to secondary chloride in order to couple.
PDF of Patent
+ - US 4,721,723
+ - US 4,721,723
~>US4,721,723 PDF Document
+ - WO 96/36636
Condensation, Prins, resolution, reduction, substitution, deprotection
+ - Dothiepin
+ -
Dothiepin (dosulepin) is a well
trusted tricyclic anti-depressant
with some tranquillising properties.
+ - US 3,527,766
Synthesis of starting material:-
benzenethiol and 2-chloromethyl-benzoic acid or
3H-Isobenzofuran-1-one (alkyl vs acyl attack)?
+ - Ownership Details
+ - Aesica Limited
03600002
Name & Registered Office:
AESICA LIMITED C/O JOHN MARSHALL & CO
6 BELL VILLAS, PONTELAND
NEWCASTLE UPON TYNE NE20 9BE
Company No. 03600002
Status: Active Date of Incorporation: 17/07/1998 Country of Origin: United
Kingdom Company Type: Private Limited Company Nature of Business (SIC(03)): 5530
- Restaurants Accounting Reference Date: 31/03 Last Accounts Made Up To:
31/03/2006 (TOTAL EXEMPTION SMALL) Next Accounts Due: 31/01/2008 Last Return
Made Up To: 17/07/2006 Next Return Due: 14/08/2007 Last Members List: 17/07/2006
Previous Names: No previous name information has been recorded over the last 20
years.
Restaurant?
+ - Aesica Pharmaceuticals Limited
05188033
Name & Registered Office: AESICA PHARMACEUTICALS LIMITED
WINDMILL INDUSTRIAL ESTATE CRAMLINGTON
NORTHUMBERLAND NE23 3JL
Company No. 05188033
+ - Status: Active Date of Incorporation: 23/07/2004
Country of Origin: United Kingdom
Company Type: Private Limited Company
Nature of Business (SIC(03)): 2441 -
Manufacture of basic pharmaceutical prods
Accounting Reference Date: 31/08 Last Accounts
Made Up To: 31/08/2005 (FULL) Next Accounts Due:
30/06/2007 Last Return Made Up To: 23/07/2006
Next Return Due: 20/08/2007 Last Members List:
23/07/2006 Previous Names: Date of change
Previous Name 17/08/2004 EVER 2414 LIMITED
+ - EVER 2414 Limited
Name & Registered Office: EVER 2414 LIMITED
CENTRAL SQUARE SOUTH ORCHARD STREET
NEWCASTLE UPON TYNE NE1 3XX
Company No. 04739682
Status: Dissolved 04/10/2005 Date of Incorporation: 18/04/2003
Country of Origin: United Kingdom Company Type: Private Limited Company
Nature of Business (SIC(03)): 2441 - Manufacture of basic pharmaceutical prods
Accounting Reference Date: 30/04 Last Accounts Made Up To:
(NO ACCOUNTS FILED) Next Accounts Due: 18/02/2005 Last Return
Made Up To: 18/04/2004 Next Return Due: 16/05/2005 Last Members List:
18/04/2004 Previous Names: Date of change
Previous Name 17/08/2004 AESICA PHARMACEUTICALS LIMITED 29/01/2004
EVER 2083 LIMITED
+ - Aesica Trustee Company Limited
05649537
Name & Registered Office: AESICA TRUSTEE COMPANY LIMITED
AESICA PHARMACEUTICALS LIMITED
WINDMILL INDUSTRIAL ESTATE CRAMLINGTON
NORTHUMBERLAND NE23 3JL Company No. 05649537
Status: Active Date of Incorporation: 08/12/2005 Country of Origin: United
Kingdom Company Type: Private Limited Company Nature of Business (SIC(03)): 2441
- Manufacture of basic pharmaceutical prods Accounting Reference Date: 31/12
Last Accounts Made Up To: (NO ACCOUNTS FILED) Next Accounts Due: 08/10/2007
Last Return Made Up To: 08/12/2006 Next Return Due: 05/01/2008 Last Members
List: 08/12/2006 Previous Names: No previous name information has been recorded
over the last 20 years.
Note
Eversheds (Lawyers) Central Square South
Orchard Street
Newcastle upon Tyne
NE1 3XX United Kingdom
+ - Patent Portfolio
+ - Espace Search 02-Feb-2007
3 patents
STABLE PHARMACEUTICAL APPLICATION FORM FOR PAROXETIN ANHYDRATE
"The invention relates to medicaments containing paroxetin anhydrate or
pharmaceutically compatible salts thereof and lipophiles and/or semi-lipophilic
carriers."
+ - PROCESS FOR THE RACEMISATION OF 1-BENZYL-4-(4-FLUOROPHENYL)-3-HYDROXYMETHYL-
1,2,3,6-TETRAHYDROPYRIDINE TO BE USED AS INTERMEDIATE IN THE SYNTHESIS OF
PAROXETINE
"A process for the racemisation of enantiomerically enriched
1-benzyl-4-(4-fluorophenyl)-3-
hydroxymethyl-1,2,3,6-tetrahydropyridine which is a useful intermediate in the
preparation
of paroxetine. Formula (A) means that the compound (I) has an enantiomeric
excess of one
enantiomer over the other enantiomer. R1 and R2 are defined as in claim 1."
US6949650, pdf local drive
+ - RECOVERY AND RECYCLING OF CHIRAL TARTARIC ACID RESOLVING AGENTS
"A process for the recovery of substituted tartaric acid resolving agents from
resolution process liquors comprising organic solvents, wherein the
substituted tartaric acid derivatives are neutralised by adding a base,
extracted into an aqueous phase and crystallised from the aqueous phase
by addition of a mineral acid in the presence of an organic solvent."
~>USApp20050085665-1
+ - 5 patents from USPTO Assignee "Aesica"
search conducted 16th March 2007
10495359 NONE US20050085665 AESICA PHARMACEUTICALS
10362531 6949650 US20040014786 AESICA PHARMCEUTICALS LTD.
09423749 6326496 AESICA PHARMACEUTICALS LTD.
09949899 6596309 US20020058063 AESICA PHARMACEUTICALS LTD.
08424517 5599969 AESICA PHARMACEUTICALS, LTD.
+ - Lexis-Nexis Butterworth (LNB) Search
12th Feb 2007. 1 - 49 (note not all may be relevant to this company).
Turbine Trouble, Evening Chronicle 02-Feb-2007.
Planning permission refused to have a wind turbine.
The story slightly misses the point "Drugs companies
in Northumberland hoping to slash their energy bills
by installing turbines ..." At the time of writing in the UK
a lot of money can be made through ROCs (Renewable
Energy Obligation Certificates. Saving energy is a usually
a secondary consideration.
Flight Fears block plans to cut bills, 1-Feb-2007
see above.
Second Firm Bids for Windturbines 17-Jan-2007
13-Dec-2006 "PHARMACEUTICAL company Aesica will
nearly double its revenues after buying a factory in north
London from industry giant Merck & Co.
Aesica, based in Cramlington, Northumberland, is to take
over Merck's facility at Ponders End, in Enfield, north London,
for an undisclosed sum. The deal is expected to take
Aesica's turnover to between £50m and £60m. The company
will also be hiring new staff.
Its Cramlington site, bought out from BASF in 2004, currently
employs around 160 direct employees, and Aesica will take
on another 74 in Enfield from Merck, as well as hiring at least
another 20 staff there over the next few months."
Drug firm delighted by 10-year contract BYLINE: By Graeme King, The Journal
SECTION:
BUSINESS LOCAL, Pg. 3 LENGTH: 352 words A multi-million pound deal for a
Northumberland drug company has given the industry a lift just days after rival
Pfizer
announced it was selling up in Morpeth, putting 600 jobs in jeopardy. Aesica
Pharmaceuticals from Cramlington has signed a 10-year deal with US company
Myriad
Pharmaceuticals to supply an ingredient for its new anti-Alzheimer's drug. Chief
executive
Dr Robert Hardy said the deal was a great achievement just five months after
Aesica was
created in a management buy-out from BASF. And there is a good chance Aesica's
140-strong team could grow if demand for the Flurizan product still being tested
in clinical
trials is as strong as expected. Aesica has already taken on a handful of new
staff for
projects it is currently working on, and Dr Hardy said there could be more to
come. He
said: "Depending on how big this grows, there could be expansion on site here in
the
future. "This deal secures a longer term future for us. If this is successful,
we've got
business for 10 years, rather than for the shorter term. "Those products we have
at the
moment are very good, but in five to six years more, they won't be making the
returns they
are now." The massive deal is important for 35m turnover Aesica as its current
products
only have a shelf life of around five to six years, and new products are needed
to secure
the long term future of the workforce. Dr Hardy said: "It's very important to
come up with a
pipeline of new products. It's clearly one of our prime objectives. The company
is achieving
everything we expected it to. We are well ahead of where we expected to be with
new
products, and we are looking at another product as well as this one. "Flurizan
is potentially
a blockbuster in terms of sales for Myriad and we have a 10-year agreement as
primary
supplier." Dr Hardy said early indications were that Flurizan was effective for
Alzheimer's
and also for prostate cancer. Dr Hardy said Aesica was very content to be
located in the
North-East and he did not think the loss of Pfizer was any reflection of the
business
environment in the region. LOAD-DATE: February 3, 2005 LANGUAGE: ENGLISH
Copyright 2005 Newcastle Chronicle & Journal Ltd
+ - Quality
+ - cGMP
EU Link
EudraLex
The Rules Governing Medicinal Products in the European Union
Volume 4
EU Guidelines to
Good Manufacturing Practice
Medicinal Products for Human and Veterinary Use
Part II
Basic Requirements for Active Substances used as Starting Materials
Iso 9000 - 2000
MHRA
FDA
+ - Management
+ -
* Robert Hardy, Managing Director
* Adam Sims, Finance Director
* Alan Rankin, Sales and Marketing Director
* Chris Gowland, Operations Director
* John McConnell, Human Resources Director
LNB Pending
Questions
Why two companies (trust and pharma Co)?
Where is the future direction of the company?
Is it only acquisition, or
innovation?
"It's very important to come up with a
pipeline of new products." How?
Where are sources of competitive intelligence
and hence strategic planning
Aesica, or
Backers?
What is known about the banker's portfolio (ie
do they have any other pharma Cos on their
books)?
How important were the wind turbines (ie
ROCs) to Aesica Cash flow?
US6949650 Who were the inventors?
Note Very much a work in progress.
|
| |